APCS and idiopathic pulmonary fibrosis: More importantly, a recombinant form of human SAP (PRM-151) has been proposed as a novel anti-fibrotic immunomodulator in IPF patients, based on phase 2 randomized and placebo-controlled trials, with no serious adverse reactions (75–77), which encourages clinical trials to evaluate the efficacy of this short pentraxin, in addition to PTX3, in the treatment of IA.